FTSE 100 Live: London stocks shrug off Iran's Hormuz terms as miners lend support

FTSE 100 was up around 51 points to 10,919 as Brent crude rose above $82 per barrel. Precious metals gains lifted Fresnillo, up about 5%, and Endeavour Mining. The move followed reports of Iran-Oman draft terms on Strait of Hormuz shipping restrictions. Investors also awaited US non-farm payrolls.

Original reporting
Published Aug 7, 2026, 10:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FTSE 100 Live: London stocks shrug off Iran's Hormuz terms as miners lend support — source image
Decision brief

The 30-second read

$AZNBullishMed
01

Why it matters

Precious-metals miners are bid on gold and silver strength, while energy names benefit from higher Brent. Separately, several single-stock catalysts appear: Goodwin’s sale exploration, Genel’s takeover rejection and DNO’s public offer, and Oxford BioMedica’s guidance cut.

02

Market read

Traders get both macro-driven commodity beta (gold, silver, Brent) and several company-specific catalysts that can drive outsized intraday moves.

03

What to watch

The article notes unusually wide payroll estimate ranges; a surprise could quickly rotate out of commodity beta and into defensives, reversing early winners.

Relevance 6/10Novelty 5/10Timing: pre-market and early London session, ahead of US non-farm payrolls later today

Background

The piece frames early FTSE 100 trading around Iran-Oman Strait of Hormuz draft terms and an upcoming US non-farm payrolls release, with commodities driving sector moves.

Company-level read

Ticker impact

$AZNBullishLow confidence
Context

AstraZeneca recovers some losses as the risk of a merger with Bristol-Myers Squibb is described as having receded.

Expected impact

Potential for continued stabilization, but likely headline-driven and reversible.

Evidence & confidence

The article frames the move as receding merger risk without new deal terms or a definitive resolution, so incremental information is limited.

$RTOBearishLow confidence
Context

Rentokil Initial is down about 1.6% in early trade while the index is supported by miners and oil strength.

Expected impact

Limited conviction without a fresh catalyst.

Evidence & confidence

The article lists the decliner but does not provide a new company event or driver for RTO.

Market effects

Higher Brent and stronger gold/silver are driving cross-asset beta into miners and energy, while oil-sensitive sectors (airlines) lag.

UK large-caps are trading as a proxy for Middle East shipping risk and US payroll expectations.

Hormuz-related shipping terms and US jobs data can move global rates, inflation expectations, and commodity complex pricing.

Counterpoint

The index strength may be temporary if gold and oil gains fade after Hormuz headlines or if payrolls surprise shifts rate expectations.

Key entities

  • Fresnillo PLC

    Precious-metals miner leading FTSE 100 gains on gold and silver price strength.

  • Goodwin PLC

    Engineering group confirming it is exploring a sale of part of its mechanical engineering division.

  • Genel Energy PLC

    Rejecting a £202 million takeover approach while DNO publishes a 69p-a-share cash offer.

  • Oxford BioMedica PLC

    Cutting 2026 guidance with EBITDA expectations slashed by about half.

  • BP PLC

    Up on Brent crude rising back above the low-$80s amid Hormuz-related supply concerns.

Related articles

$AZNMed

AstraZeneca (AZN) And Bristol Myers Squibb (BMY) Merger Speculation Denied As Drone Delivery And AI Reshape Pharma Supply Chain

Reuters reports a senior source close to AstraZeneca and Bristol Myers Squibb denied merger talks, saying no discussions are underway and no deal was planned. The denial follows a Financial Times report of preliminary talks for a potential roughly $400 billion combination. The focus shifts to drone last-mile delivery and Kenco’s rollout of AI agents in pharma logistics.

$AZNMed

NICE Expands First-Line Options for Two Blood Cancers

NICE issued final draft guidance recommending AstraZeneca’s acalabrutinib (Calquence) in two first-line combination regimens in England for untreated mantle cell lymphoma and chronic lymphocytic leukaemia. For MCL, acalabrutinib plus bendamustine and rituximab for ~350 patients not eligible for stem cell transplant. For CLL, acalabrutinib plus venetoclax for ~440, including high-risk disease. NHS funding is due within 90 days; trials report longer progression-free survival and improved overall s

$AZNMedAI 8/10

Pharma megamerger speculation collapses: No AZ

Reuters reports, citing a confidential source, that AstraZeneca and Bristol Myers Squibb have not held substantive merger talks and that no deal or discussions exist. The denial reversed market moves: AstraZeneca shares rose about 2.9% while BMS fell about 2.6%. Speculation followed a Financial Times report of potential $400 billion exploratory talks.

$AZNMed

AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation

Reuters, citing a senior source, said there is no deal and no current merger discussions between AstraZeneca and Bristol Myers. The clarification followed Financial Times speculation about talks that could have created a nearly $400 billion pharma group. AstraZeneca shares reportedly rebounded about 3% after Reuters; Bristol Myers fell about 3%. Neither company commented.

$BMYMed

Bristol Myers Merger Denied: What It Exposed

Reuters reported, citing a senior source, that AstraZeneca and Bristol Myers Squibb had no discussions and no viable merger talks, reversing earlier reports of preliminary talks. AstraZeneca shares fell about 9% on the rumor; Bristol Myers was steadier. The companies overlap in oncology assets including Opdivo and Imfinzi, which would have raised antitrust issues.